Drug General Information |
Drug ID |
D0Q0KD
|
Former ID |
DNC012297
|
Drug Name |
1-Propyl-3-o-tolyl-piperidine hydrochloride
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Canonical SMILES |
C1=CC(=CN=C1)C(=O)CCl.Cl
|
InChI |
1S/C7H6ClNO.ClH/c8-4-7(10)6-2-1-3-9-5-6;/h1-3,5H,4H2;1H
|
InChIKey |
PBIUDEUWYGBHDW-UHFFFAOYSA-N
|
Target and Pathway |
Target(s) |
D(2) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Rap1 signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Gap junction
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Alcoholism
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Dopamine receptor mediated signaling pathway
|
Nicotine pharmacodynamics pathway
|
Reactome
|
Dopamine receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
Genes and (Common) Pathways Underlying Drug Addiction
|
GPCR ligand binding
|
GPCR downstream signaling
|
Nicotine Activity on Dopaminergic Neurons
|
References |
REF 1 | J Med Chem. 2003 Jan 2;46(1):161-8.New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. |